Introduction
Influenza viruses are the major causative agents of respiratory diseases that are responsible for yearly global epidemics infecting millions of people and causing serious illnesses and deaths worldwide [1, 2] . The prevention and control of influenza virus infection relies mostly on effective vaccinations. [3] . Conventionally, influenza vaccines are produced using chicken eggs procured from qualified facilities. This method requires millions of eggs, resulting in the need for advanced order prior to production. It takes between 6 and 12 months to produce and distribute the egg-derived vaccines once manufacturing activities have begun. Egg-derived vaccines can also be produced and distributed between 6 and 12 months once the process has started [4] . The disadvantage of the long production time was confirmed during the 2009 H1N1 epidemic when only 22% of the expected vaccine doses were delivered within the first 6 months after the epidemic was reported [5, 6] . Moreover, it may not be feasible to manufacture egg-based vaccines following pandemics caused by highly pathogenic avian influenza virus (HPAIV), which can kill chickens rapidly. Therefore, the need for an alternative influenza vaccine production method, such as cell-based technology, is apparent [6] .
Madin-Darby canine kidney (MDCK) cells are frequently used for the primary isolation of influenza viruses because of their high susceptibility to infection with various influenza strains [7, 8] . Additionally, cell culture-based influenza vaccine production is becoming important as an alternative to egg-based processes [9] [10] [11] , and MDCK cell culturederived influenza vaccines have been approved by the European Medicines Agency [12] and Korean SK Chemicals [13] . However, the production of influenza vaccines using cell culture has some disadvantages. For example, the volumetric yield of the cell-based flu virus is about 4-fold lower than the egg-based process [14] . This means largevolume bioreactors are required, resulting in high manufacturing costs, which may restrict the use of cell culture-based platforms for influenza vaccine production.
To overcome the current limitations of cell culture-based influenza virus production, we continuously passaged the A/Puerto/8/1934(H1N1) virus (commonly used as the seasonal and pandemic vaccine backbone strain) in MDCK cells to generate an MDCK-adapted high-growth (HG) strain. In addition, throughout the process, we selected several MDCK-adapted PR8 backbone strains by plaque purification. These strains grew up to 10 to 100 times more than the parental strain. Genetic analysis revealed that the selected HG viruses had specific mutations in their internal genes and showed higher polymerase activity compared with the parental virus. Furthermore, in the context of the HG PR8 backbone, various Rg viruses maintained this high-growth property in both attached and suspended MDCK cells.
Materials and Methods

Cells
MDCK (ATCC CCL-34) cells obtained from ATCC were maintained in EMEM (LONZA, Switzerland) using 5% fetal bovine serum (FBS), 1% non-essential amino acids (Gibco, USA), and 1% penicillin/streptomycin (Gibco, USA). Vero cells were cultured in Dulbecco's modified Eagle's MEM (LONZA, Switzerland) with 10% FBS. Cells were maintained at 37°C in 5% CO
2
. The MDCK suspension cells were provided by the Green Cross Corporation [15] .
Influenza A/Puerto/8/1934 Virus Adaptation in MDCK Cells
The A/Puerto/8/1934 (PR8, H1N1) virus was propagated in MDCK cells. The PR8 virus was serially passaged 48 times in MDCK cells supplemented with 2 μg/ml TPCK-trypsin (SigmaAldrich, USA) until it acquired the high-growth property (10 8 . 0
PFU/ml).
Plasmids and Rescue of Reverse Genetic Viruses
To generate the HG PR8 backbone virus, each of the eight gene segments of the HG PR8 viruses was amplified by reverse transcription-PCR from plaque-purified viruses and cloned into the vpHW2000 vector, as described in a previous study [16] . All recombinant and point mutation viruses (see Tables 1 and 2) were rescued in Vero and MDCK coculture mixtures (3:1 ratio) as previously described [16] . All rescued viruses were fully sequenced to double check the absence of unwanted mutations.
Site-Directed Mutagenesis
The individual characteristic mutations in PB2, PB1, PA, M, and NS were introduced into the parental PR8 internal backbone by site-directed mutagenesis using the Gene Tailor site-directed mutagenesis system (Invitrogen, USA) based on the manufacturer's instructions. We resequenced the entire genome to confirm there was no introduction of unwanted mutations.
Growth Curve of Viruses in MDCK Cells
MDCK cells were inoculated with each mutant virus at a 0.001 MOI (multiplicity of infection), respectively, and incubated at 37 ). The viral growth property was measured in MDCK cells with three independent trails as previously described [17] . A hemagglutination (HA) test was adapted to determine the virus endpoint titers with 
0.5% turkey erythrocytes [17] .
Experimental Infection of Mice
Groups of 6-week-old female BALB/C mouse (n = 10) were intranasally inoculated with each of 10 /50 μl of Rg viruses, which contained double, triple, or quadruplicate amino acid substitutions. Body weights and survival were recorded daily for 14 days.
Virus Propagation in 5-L Single-Use Bioreactors
MDCK suspension cells were cultured in 5-L single-use bioreactors (PBS Biotech Inc., USA) with a working volume of 3 L, as previously described [18] . When the cell density reached about 1 × 10 6 cells/ml, viruses at an MOI of 0.001 and TPCK-trypsin (5 μg/ml) were added to the bioreactors. The virus was yielded at 12, 24, 36, 48, 60, and 72 hpi, and was titrated in MDCK cells by TCID 5 0 [19] .
Luciferase Minigenome Reporter Assays
The luciferase reporter plasmids (vpHW72-Luc and canine pHW72-Luc), which contained the Vero cell-and MDCK celldriven polI transcription unit, respectively, were generated in the backbone of vpHW72-Luc, as previously described [17, 20] . Briefly, Vero or MDCK cells were cultured in 24 h prior to use and 0.1 μg each of the vpHW72-Luc or canine pHW72-Luc, vpHW2000-PB2, vpHW2000-PB1, vpHW2000-PA, vpHW2000-NP, and pCMV-β-galactosidase plasmids were transfected into each cells with TransIT-LT1 transfection reagent, as previously described [16] . Fresh DMEM (Gibco, USA) containing 5% FBS and incubated at 37 o C was used to replace the transfection medium after 4 h. Luciferase activity was assayed in triplicate using the luciferase assay system with each of the cell lysates subsequent to washing with PBS after 24 h (Promega, USA). The results were normalized to the β-galactosidase activity level of the cells.
Ethics
General animal care guidelines mandated under the Guidelines for Animal Use and Care of the Korea Center for Disease Control were used for the mouse experimental protocols in this study. 
Statistical Analysis
GraphPad Prism ver. 5.00 for Windows (GraphPad Software, USA) was used to analyze the data. Probability values of less than 0.05 (p < 0.05) were considered statistically significant.
Results
Growth Efficiency and Genetic Characterization of MDCK-Adapted HG Viruses
To overcome the relative low growth property of influenza vaccine strains in MDCK cell lines compared with the embryonated chicken egg-derived culture method, we generated an MDCK-adapted A/Puerto/8/1934 vaccine backbone strain by serial passage in MDCK cells. The parental PR8 virus could make plaques after 2 days of infection in MDCK cells (Fig. 1A ) and reach peak infectious virus titers of about 6.83 log 1 0
PFU/ml at 48 h (Fig. 1B) . However, following 48 serial passages including four rounds of plaque purification on the 15 1 0 PFU/ml (Fig. 1B , a 10-fold increase over parental, p < 0.001). To obtain a single HG PR8 plaque, we plaque-purified clone. Furthermore, we found that these amino acid substitutions were stable and maintained for a further 15 passages, giving rise to the HG-48 clone.
To explore the potential role of mutation of each of these four amino acids in the accelerated growth kinetics, we generated mutants of each HG virus using reverse genetics, as previously described [16] . Each HG virus (PB2
, and NS1
) was tested for plaqueforming characteristics and growth kinetics in MDCK cells and was compared with the parental PR8 virus (Figs. 1C  and 1D ). Three HG viruses (PB2
) exhibited similar plaque phenotypes (homogeneous) although they were all larger than those of the PR8 parental virus. However, the PB1
virus formed small punctiform plaques with a mean size of 0.45 ± 0.11 mm compared with clear circular plaques of 1.04 ± 0.64 mm for the PR8 virus (Fig. 1C) . As for the growth properties, all four HG viruses (PB2
) showed significantly increased viral titers (more than 10 times higher) compared with the PR8 parental virus (6.8 log 1 0 PFU/ml) (p < 0.01, Fig. 1D ). Of these, the NS1 PFU/ml at 48 hpi. These results indicate that each substitution within the HG-48 clone contributed to the increased viral titer of this clone in MDCK cells.
MDCK-Adapted HG Viruses Containing a Combination of Mutations Have Enhanced Growth Characteristics
To determine if there are any synergetic effects of the amino acid substitutions in the PB2, PB1, M1, and NS1 segments, we generated various HG viruses with two, three, or four amino acid substitutions and evaluated their replication properties in MDCK cells. We found that three HG viruses (HG-PB1M1, HG-PB2PB1M1, and HG-PB1M1NS1), grew to 8.52, 8.53, and 8.58 log 1 0 PFU/ml at 48 hpi (Table 2) . Strikingly, the HG-PB1M1NS1 combination showed the highest virus titer, thus suggesting that the PB1 To determine the pathogenicity of the HG viruses in mice, we determined the 50% mouse lethal dose (MLD 5 0 ) ( Table 2 ). The parental PR8 virus MLD First, we tested the one-step growth curves of the parental PR8 and HG viruses (PR8/HG-PB1M1, PR8/HG-PB2PB1M1, and PR8/HG-PB1M1NS1) in MDCK cells. As expected, PR8/HG-PB1M1, PR8/HG-PB2PB1M1, and PR8/ HG-PB1M1NS1 showed increased viral titers compared with their parental PR8 virus (48 hpi, 7.0, 7.15, and 7.6 log 1 0 TCID 5 0 /ml; Fig. 2A) . Moreover, the PR8/HG-PB1M1NS1 virus grew more rapidly and exhibited the highest titer in MDCK cells at 24-72 hpi ( Fig. 2A) .
For the seasonal H1N1 virus study, although similar replication kinetics were observed at early time points (12 and 24 hpi), the CA/07/HG-PB1M1 and CA/07/HG-PB1M1NS1 (p < 0.05) viruses showed significantly high titers compared with the parental CA/07 virus at 36, 48, and 72 hpi (Fig. 2B) . For the seasonal H3N2 study, the Perth/HG-PB1M1 and Perth/HG-PB2PB1M1 viruses showed similar growth kinetics with the parental A/Perth virus. However, the Perth/HG-PB1M1NS1 virus exhibited significantly higher viral titers (more than 50-fold increased) at all time points (12-72 hpi) than those of the parental A/ Perth virus (p < 0.05) (Fig. 2C) , and showed the highest virus titer at 48 hpi (7.25 log 1 0 TCID 5 0 /ml). As for the avian H5N1 virus, ΔW150/HG-PB1M1 and ΔW150/HG-PB2PB1M1 showed similar growth kinetics to the parental A/ΔW150 virus at all time points. Interestingly, the ΔW150/HG-PB1M1NS1 virus exhibited significantly higher growth titers starting at 24 hpi compared with the parental A/ ΔW150 virus (p < 0.001) and reached a peak viral titer of 7.25 log 1 0
/ml at 48-60 hpi (Fig. 2D ). These results demonstrate that the HG-PB1M1NS1 combination significantly enhances the replication of pH1N1, H3N2, and H5N1 vaccine strains in MDCK cells.
Application of HG-Backbone Viruses in Large-Scale MDCK Suspension Cultures
In recent years, the need for development of a serum-free suspension cell culture process for influenza vaccine production has become apparent [15] . To determine which HG virus elicited the greatest increase in vaccine productivity in MDCK suspension cells, each of the HG viruses were inoculated into vaccine-manufacturing MDCK suspension cells (5-L bioreactors) and samples of the culture medium were subjected to the TCID significant increases in viral titers over the parental PR8 virus (Fig. 3A) .
For the seasonal H1N1 virus, although all HG viruses showed increased virus titers at 24-36 hpi compared with the parental CA/07 virus, CA/07/HG-PB1M1NS1 showed the highest virus titer (7.25 log 1 0
/ml) at 48 hpi (Fig. 3B) . Furthermore, with regard to the seasonal H3N2 virus, Perth/HG-PB1M1NS1 conferred significantly higher titers than the parental Perth virus from early time points (12-24 hpi, p < 0.001) and reached up to 7.25 log 1 0
/ml at 48 hpi, whereas the other HG backbone viruses (Perth/ HG-PB1M1 and Perth/HG-PB2PB1M1) showed comparable viral growth curves to the parental Perth virus at all time points (Fig. 3C) .
It is noteworthy that the avian ΔW150/HG-PB1M1NS1 virus showed significant high-growth properties compared with the parental A/ΔW150 virus at all the time points except 12 hpi (Fig. 3D) . Although the ΔW150/HG-PB1M1 virus also exhibited high growth at 36 hpi (p < 0.001), its growth slowed and eventually reached a similar titer as the parental A/ΔW150 virus (6.5 log /ml, respectably. These results suggest that the genes of the HG-48 clone do not contribute to increased virulence in mice.
The HG-Backbone Enhances Polymerase Activity
To investigate the effect of mutations in the polymerase gene of the HG-backbone, we performed a polymerase activity test using a luciferase reporter gene assay in Vero cells. At 37°C, polymerase complexes containing the individual PB2 ) was slightly lower (120%) than that of PB2
single mutant (135%) at 37°C, but still higher than the parental polymerase complex.
To extend these studies to MDCK cells, we generated a modified luciferase reporter gene system driven by a canine RNA PolI promoter instead of the human RNA PolI promoter and found that the polymerase complexes containing the individual PB2 (141%, p < 0.01) mutations showed significantly higher polymerase transcription than that of the parent polymerase complex (Fig. 4B) . Coexpression of the PB2 also significantly elevated the polymerase activity of the HG virus (150%, p < 0.01, Fig. 4B ). Thus, these polymerase gene mutations result in increased polymerase activity in MDCK cells.
Discussion
Mammalian cell culture systems have the potential to be a more robust platform for vaccine generation than the egg production system. The biggest drawback of amplification of influenza viruses in embryonated eggs is the occurrence of antigen variants of parental vaccine strains [20, 21] . In contrast, the HA of influenza viruses amplified using cell culture is typically the same as that of the original strain [22] [23] [24] . Considering these advantages, cell culture-based technology has recently been used to manufacture influenza vaccines, some of which are already licensed in Europe [12] , Asia [13] , and Latin America [25, 26] . However, despite the advantages of cell culture-based influenza vaccine preparation, this method is used in the production of only a small percentage of the influenza vaccines available on the market [27] . This is because cell culture-based vaccines may bring many problems, including higher cost, batch variation, and risk of mycoplasma contamination. To overcome the relatively low viral titer of the cell culturebased method, which leads to the increased vaccine cost compared with egg-based influenza vaccine manufacturing, we adapted the current influenza A vaccine backbone strain A/Puerto/8/1934 (PR8, H1N1) in MDCK cells. Moreover, because recombinant vaccines have proven to be a practical counterplan to traditional influenza vaccines, we selected a high-growth clone, HG-48, that showed a consistently large plaque size and virus titers 10-100 times higher than the parental virus. Interestingly, full-length sequencing showed that the amino acid mutations observed after 48 passages were identical to those at 33 passages, meaning that these mutations were consistently maintained in the HG-48 clone. These data suggest that each of the unique gene substitutions is very stable during MDCK replication (Table 1) .
When we applied the HG-backbone combination to the recent human seasonal influenza A vaccine strains (H1N1, H3N2, and H5N1), the HG-PB1M1NS1 constellation consistently conferred significantly higher virus titers even at early time points for H1N1 and H3N2. Furthermore, the HG-PB1M1NS1 composition of the HG backbone efficiently enhanced the H5N1 virus at all the tested time points. Based on our studies, the M1 [28, 29] , further study is needed to understand the mechanism of action underlying the enhanced growth of viruses with the M1 Several studies have reported the profitable development of bioreactor-based suspension cell culture processes using serum-free medium for influenza vaccine production [30] [31] [32] [33] . Hu et al. [31] reported the feasibility of the development of an MDCK cell-based inactivated H5N1 vaccine in a microcarrier-based bioreactor culture system. To this end, they used a 2 L bioreactor (1 L working volume) with peak titers reaching 10 8 -9
TCID
5 0 /ml. In 2007, the European Medicines Agency approved an MDCK cell culture-derived influenza vaccine (CCIV) (Optaflu; Novartis Vaccines) produced using bioreactors of more than 100 L [11] . To evaluate virus productivity in MDCK suspension cells, each of the HG-backbone viruses were inoculated into vaccine-manufacturing, serum-free MDCK suspension cells as 5-L large-scale preparations in bioreactors and virus replication was compared. Interestingly, all H1N1, H3N2, and avian H5N1 viruses containing the HG-PB1M1NS1 backbone consistently exhibited high viral titers, with the avian H5N1 virus showing significantly enhanced virus productivity (up to 100 times greater than parental). Therefore, our results could help establish MDCK-optimized HG-backbone large-scale vaccine production.
There are many factors that contribute to viral growth in vitro, such as cell line passage number, TPCK-trypsin concentration, media brands, and temperature. However, our selected backbone strains consistently showed significantly high virus titers and polymerase activities compared with those of the original PR8 backbone virus (three independent trials). Therefore, we believe that the selected PR8 backbone viruses have increased proliferation ability in MDCK cells.
Several studies have suggested that a second booster vaccine or increased antigenic dose is required in very young or elderly patients to induce proper protective immunity, since their immune status is immature or attenuated [34] [35] [36] . Furthermore, avian H5N1 mock-up vaccines have shown relatively low immunogenicity in mammalian hosts, which is daunting in terms of avian influenza vaccine preparedness [36, 37] . Hence, some studies have suggested increasing antigen doses to as much as 15 μg/dose to induce proper immunogenicity [38] . In light of this, production using our MDCK-adapted HG-PB1M1NS1 backbone-based vaccine in serum-free MDCK suspension cells could be a rapid and useful strategy to meet the need for high-dose HPAI vaccine preparedness.
The MDCK-adapted virus in this study exhibited stable mutations in both the PB2 and PB1 viral proteins, which are components of the RNA-dependent polymerase complex. Therefore, we first performed a luciferase reporter gene assay in Vero cells to investigate whether PB2 mutations elevated the polymerase activity of HG viruses, resulting in substantially higher transcription/ replication activity. MDCK cells have recently been approved for human vaccine production. Therefore, to further compare the polymerase activity of the MDCK cellspecific PolI promoter with that of the original human PolI promoter system, we assessed the polymerase activity, as described previously [39] . These results showed that PB2 mutations found in the HG virus confer an increase in polymerase activity over that of the parental virus. The PB2 polymerase gene is known to be associated with polymerase activity, virulence, and restriction of host range. [40] . For this reason, we checked the virulence of PB2 mutants in mice by assessing the MLD (Table 2) . Moreover, the HG backbone did not increase virulence when introduced into H1N1, H3N2, or H5N1 viruses. Thus, the HG-backbone viruses may be useful to develop safer and efficacious vaccines.
The production of a capable system to supply influenza vaccine to the world while keeping safety, immediacy, and cost-effectiveness in mind remains an important challenge for international government agencies. Taken together, our results show that the HG-backbone vaccine viruses identified in this study can improve the titers of seasonal and pandemic influenza vaccines in cultured cells. Thus, future efforts to further explore the feasibility of this method for vaccine production is warranted.
